


PHARMACEUTICAL 2023

Design Therapeutics Inc. Rank 17 of 446







RealRate

Design Therapeutics Inc. Rank 17 of 446

The relative strengths and weaknesses of Design Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Design Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Design Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 281%, being 238% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	335,119
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,776
Liabilities, Non-Current	3,051
Other Assets	4,071
Other Compr. Net Income	-3,112
Other Expenses	0
Other Liabilities	0
Other Net Income	4,285
Other Revenues	0
Property and Equipment	1,947
Research and Development	48,613
Selling, General and Administrative Expense	18,980

Output Variable	Value in 1000 USD
Assets	341,137
Liabilities	13,827
Expenses	67,593
Revenues	0
Stockholders Equity	327,310
Net Income	-63,308
Comprehensive Net Income	-64,864
Economic Capital Ratio	281%

